Navigation Links
Reportlinker Adds Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
Date:3/16/2010

NEW YORK, March 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0182980/Atherosclerosis-Or-Coronary-Artery-Disease-CAD---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Description

Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

"Atherosclerosis Or Coronary Artery Disease (CAD) – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global atherosclerosis market. The report identifies the key trends shaping and driving the global atherosclerosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global atherosclerosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

<bScope

The <bScope of the report includes:

- Annualized global atherosclerosis revenues data from 2001 to 2009, forecast forward for 7 years to 2016.

- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.

- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.

- Analysis of the current and future market competition in the global atherosclerosis market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with atherosclerosis.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global atherosclerosis market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global atherosclerosis market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global atherosclerosis market landscape? – Identify, understand and capitalize.

Companies Mentioned

GlaxoSmithKline plc

Novartis AG

Merck & Co., Inc

Table of Contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Coronary Artery Disease: Market Characterization 6

2.1 Overview 6

2.2 Coronary Artery Disease Market Size 6

2.3 Coronary Artery Disease Market Forecast and CAGR 7

2.4 Drivers and Barriers for the Coronary Artery Disease Market 9

2.4.1 Drivers of the Coronary Artery Disease Market 9

2.4.2 Barriers for the Coronary Artery Disease Market 9

2.5 Opportunity and Unmet Need 10

2.6 Key Takeaway 10

3 Coronary Aartery Disease: Competitive Assessment 11

3.1 Overview 11

3.2 Strategic Competitor Assessment 11

3.3 Product Profile for the Major Marketed Products in the Coronary Artery Disease Market 12

3.3.1 Lipitor 12

3.3.2 Crestor 12

3.3.3 Plavix 13

3.3.4 Pravachol (pravastatin sodium) 14

3.3.5 Niaspan (Niacin) 14

3.4 Key Takeaway 16

4 Coronary Artery Disease: Pipeline Assessment 17

4.1 Overview 17

4.2 Strategic Pipeline Assessment 17

4.2.1 Technology Trends Analytic Framework 17

4.3 Coronary Artery Disease Therapeutics – Promising Drugs under Clinical Development 18

4.4 Drugs under Clinical Development 19

4.4.1 Darapladib 19

4.4.2 Anacetrapib 19

4.4.3 Aliskiren 20

4.4.4 SCH 530348 21

4.5 Coronary Artery Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action 22

4.6 Coronary Artery Disease Pipeline – Pipeline by Clinical Phases of Development 23

4.6.1 Coronary Artery Disease Therapeutics – Phase III Clinical Pipeline 23

4.6.2 Coronary Artery Disease Therapeutics – Phase II Clinical Pipeline 24

4.6.3 Coronary Artery Disease Therapeutics – Phase I Clinical Pipeline 24

4.6.4 Coronary Artery Disease Therapeutics – Preclinical Pipeline 25

4.7 Discontinued / Suspended Drugs for Coronary Artery Disease 25

4.8 Key Takeaway 25

5 Coronary Artery Disease Market: Implications for Future Market Competition 26

6 Coronary Artery Disease Market: Future Players in the Cornary Artery Disease Market 27

6.1 Introduction 27

6.2 GlaxoSmithKline plc 27

6.2.1 Overview 27

6.2.2 Business Description 28

6.2.3 Cardiovascular Portfolio 30

6.2.4 Coronary Artery Disease Product Portfolio 30

6.3 Novartis AG 31

6.3.1 Overview 31

6.3.2 Business Description 31

6.3.3 Cardiovascular Portfolio 32

6.3.4 Coronary Artery Disease Product Portfolio 32

6.4 Merck & Co., Inc. 33

6.4.1 Overview 33

6.4.2 Business Description 33

6.4.3 Cardiovascular Portfolio 34

6.4.4 Coronary Artery Disease product portfolio 35

7 Coronary Artery Disease: Appendix 37

7.1 Definitions 37

7.2 Acronyms 37

7.3 Research Methodology 38

7.3.1 Coverage 39

7.3.2 Secondary Research 39

7.3.3 Forecasting 40

7.3.4 Primary Research 43

7.3.5 Expert Panels 43

7.4 Contact Us 43

7.5 Disclaimer 43

7.6 Sources 44

List of Tables

1.1 List of Tables

Table 1: Global Coronary Artery Disease Market Revenue ($bn), 2001-2009 7

Table 2: Global Coronary Artery Disease Market Forecast ($bn), 2009-2016 8

Table 3: Major Marketed Products in the Coronary Artery Disease Market, 2010 15

Table 4: Coronary Artery Disease Therapeutics –Promising Drugs Under Clinical Development, 2010 18

Table 5: Coronary Artery Disease Therapeutics – Phase III Clinical Pipeline, 2010 23

Table 6: Coronary Artery Disease Therapeutics – Phase II Clinical Pipeline, 2010 24

Table 7: Coronary Artery Disease Therapeutics – Phase I Clinical Pipeline, 2010 24

Table 8: Coronary Artery Disease Therapeutics – Preclinical Pipeline, 2010 25

Table 9: List of Discontinued Drugs for Coronary Artery Disease, 2010 25

Table 10: GlaxoSmithKline plc – Cardiovascular and Coronary Artery Disease Pipeline, 2010 30

Table 11: Novartis AG – Cardiovascular and Coronary Artery Disease Pipeline, 2010 32

Table 12: Merck & Co., Inc. – Cardiovascular and Coronary Artery Disease Pipeline, 2010 34

List of Figures

1.2 List of Figures

Figure 1: Global Coronary Artery Disease Market Revenue ($bn), 2001–2009 7

Figure 2: Global Coronary Artery Disease Market Forecast ($bn), 2009-2016 8

Figure 3: Opportunity and Unmet Need in the Coronary Artery Disease Market, 2010 10

Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Coronary Artery Disease, 2010 11

Figure 5: Technology Trends Analytic Framework of the Coronary Artery Disease Pipeline, 2010 17

Figure 6: Technology Trends Analytic Framework of Coronary Artery Disease Pipeline – Description, 2010 18

Figure 7: Coronary Artery Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 22

Figure 8: Coronary Artery Disease Pipeline by Phase of Clinical Development, 2010 23

Figure 9: Implications for Future Market Competition in the Coronary Artery Disease Market, 2010 26

Figure 10: Coronary Artery Disease Therapeutics Market – Clinical Pipeline by Company, 2010 27

Figure 11: GlobalData Methodology 39

Figure 12: GlobalData Market Forecasting Model 42

To order this report:

Pharmaceutical Industry: Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com

'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks ... Amica Insurance is sharing tips to make sure your family and vehicle are ... National Safety Council, there may be 439 deaths and an additional 50,500 serious injuries ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
Breaking Medicine News(10 mins):